Tumor Associated Lymph node T cell(FineImmune Biotechnology)

A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection.
To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.

主要研究目的：评估TAL-T细胞疗法治疗晚期恶性实体瘤受试者的安全性和耐受性。次要研究目的：评估TAL-T细胞疗法治疗晚期恶性实体瘤受试者的有效性。